多点扫描矩阵激光联合康柏西普治疗重度非增殖型糖尿病视网膜病变的临床效果观察

Clinical observation of multi-point scanning matrix laser combined with Conbercept in treatment of severe non-proliferative diabetic retinopathy

摘要:

目的 观察多点扫描矩阵激光联合康柏西普治疗重度非增殖型糖尿病视网膜病变的临床疗效。方法 选取2019年1月—2022年1月河北省眼科医院诊治的重度非增殖型糖尿病视网膜病变患者76例，随机分为对照组（38例，康柏西普治疗）和联合组（38例，康柏西普联合多点扫描矩阵激光治疗）。比较治疗前，治疗后1个月、3个月、6个月后两组最佳矫正视力（BCVA）字符提高数、黄斑中心凹厚度（CMT）；比较两组的临床疗效和不良反应。结果 两组治疗前，治疗后1个月、3个月、6个月的BCVA字符提高数及CMT比较，结果 ①不同时间点的BCVA字符提高数、CMT有差异（P <0.05）；②两组的BCVA字符提高数、CMT有差异（P <0.05），联合组与对照组相比BCVA字母提高数比较多，相对视力改善效果较好，CMT比较低，相对黄斑区改善效果较好；③两组的BCVA字符提高数、CMT变化趋势有差别（P <0.05）。两组总有效率比较，差异有统计学意义（P <0.05），联合组高于对照组。两组随访期间均未发生与治疗相关的严重不良反应。联合组注射后一过性眼压升高及局部球结膜下出血各1例，未处理即在1周内恢复正常。结论 多点扫描矩阵激光联合康柏西普可改善重度非增殖型糖尿病视网膜病变视力及黄斑水肿，提高临床疗效，且安全可靠。

Abstract:

Objective To observe the clinical efficacy of multi-point scanning matrix laser combined with Conbercept in the treatment of severe non-proliferative diabetic retinopathy.Methods Seventy-six patients with severe non-proliferative diabetic retinopathy who visited our hospital from January 2019 to January 2022 were selected and randomly divided into the control group (38 cases, treated with conbercept) and the combined group (38 cases, multi-point scanning matrix laser treatment combined with conbercept therapy). The best corrected visual acuity (BCVA) character improvement, central macular thickness (CMT) before treatment, 1, 3, and 6 months after treatment between the two groups were compared. The clinical efficacy and adverse reactions were compared between the two groups.Results Compared with the control group 1, 3, and 6 months after treatment, the improvement of BCVA characters and CMT showed: There were differences in BCVA character improvement and CMT between different time points (P < 0.05); There were differences in the improvement of BCVA characters and CMT between the control group and the combined group (P < 0.05); Compared with the control group, the combined group increased more BCVA letters, had better relative visual acuity improvement, lower CMT, better relative macular improvement effect; The change trend of BCVA or CMT character improvement were different between the control group and the combined group (P < 0.05). The total effective rate of the two groups was significantly different (P < 0.05), and the combined group was higher than that of the control group. No serious adverse reactions related to treatment occurred during follow-up in both groups. There were 1 case of transient intraocular pressure increase and 1 case of local subconjunctival hemorrhage in the combined group after injection, which returned to normal within 1 week without treatment.Conclusion Multi-point scanning matrix laser combined with Conbercept can improve severe non-proliferative diabetic retinopathy visual acuity and macular edema, improve clinical efficacy, and is safe and reliable.